A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Solid Tumors
  • Age: Between 18 - 99 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation. 2) Unresectable or metastatic disease. 3) Available and prior therapy: a. no available treatment with curative intent, b. no available standard-of-care treatment or patient is ineligible or declines treatment, except c. in Phase 2 NSCLC cohorts, patients must have previously received treatment with at least a platinum-containing chemotherapy regimen and checkpoint inhibitor therapy.

You may not be eligible for this study if the following are true:

  • 1) Active brain metastases. Patients are eligible if brain metastases are adequately treated and patients are neurologically stable (except for residual signs or symptoms related to the central nervous system (CNS) treatment) for at least 2 weeks prior to enrollment without the use of corticosteroids or are on a stable or decreasing dose of = 10 mg daily prednisone (or equivalent). 2) Patients with carcinomatous meningitis. 3) History of significant hemoptysis or hemorrhage within 4 weeks of the first dose date. 4) Undergone major surgery within 4 weeks of first dose date.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.